mRNA or any other medication cannot be truly effective or even harmful if a genetic mutation is overlooked

By SWA

The effectiveness of mRNA vaccines or therapies can indeed be influenced by several factors, including our knowledge of the specific target and the presence of genetic variations such as (example) altered TP53 genes. 

Brief explanation:

  1. Specific Target Knowledge: mRNA technologies, such as mRNA vaccines, work by delivering a specific piece of genetic code to our cells. This genetic code instructs our cells to produce a specific protein, which in turn triggers an immune response or performs a therapeutic function. The success of this approach heavily depends on accurately identifying and targeting the right protein or molecular structure. If the target is not well understood or incorrectly identified, the mRNA molecule may not produce the intended effect.

  2. Inherited Altered TP53 Genes: TP53 is a gene that plays a crucial role in regulating cell growth and maintaining genomic stability. Mutations or alterations in the TP53 gene are linked to various cancers and can affect how cells respond to DNA damage and stress. In the context of mRNA therapies or vaccines, if someone has inherited altered TP53 genes, it might impact how their cells respond to the mRNA instructions. For instance, if the TP53 alteration affects the cell's ability to regulate growth or apoptosis (programmed cell death), it could potentially interfere with the intended action of the mRNA-based treatment.

It's important to note that the field of mRNA technology is rapidly evolving, and researchers are continually working to improve the specificity and efficacy of these treatments, taking into account various genetic factors and individual differences.

Matter of fact no medication will be truly effective or even harmful if a genetic mutation is overlooked.

 Genetic mutations can significantly impact the effectiveness and safety of medications. This concept is a key principle in the field of pharmacogenomics, which studies how genes affect a person's response to drugs. Here are some important aspects to consider:

  1. Drug Metabolism: Genetic variations can influence how an individual's body metabolizes medication. Some people may metabolize drugs too quickly or too slowly, affecting the drug's efficacy or leading to a buildup of medication in the body, which can be harmful.

  2. Drug Sensitivity: Certain genetic mutations can make individuals more sensitive to specific drugs, leading to adverse reactions even at standard dosages.

  3. Targeted Therapy: In conditions like cancer, specific genetic mutations in the tumor can predict the response to targeted therapies. Overlooking these mutations can lead to the use of less effective treatments and missed opportunities for more effective personalized therapies.

  4. Adverse Drug Reactions: Genetic factors can predispose individuals to severe adverse reactions to certain drugs. For example, the presence of certain genetic markers can increase the risk of severe skin reactions when using specific medications.

  5. Dosage Adjustments: Understanding genetic makeup can help in tailoring drug dosages. For instance, patients with certain genetic profiles might require higher or lower doses of a drug for it to be effective and safe.

Therefore, in clinical practice, it is increasingly recognized that genetic testing can be valuable in guiding medication choices and dosages for individual patients. This personalized approach aims to maximize drug efficacy and minimize harmful side effects.

© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right.
Library of Congress Card Number: LCN 00-192742

ISBN: 0-9703195-0-9

 

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more